This Interim Agreement framework reflects a long overdue acknowledgment that essential medicine supply chains cannot be left to foreign dominance, particularly by India or an adversary like China.
Zydus Pharmaceuticals, one of India’s largest generic drug makers, recalled over 22,000 bottles of a cholesterol medication on Dec. 30, 2025. AvKare, a Tennessee-based pharmaceuticals distribution company that relies on imports, recalled around 7,900 cartons of Rosuvastatin, a widely used generic statin, a day later.
CPA welcomed final passage this week of the ‘National Defense Authorization Act (NDAA) for FY2026,’ (S.1071), which has been sent to President Trump’s desk for signature. The legislation advances critical national security priorities, strengthens U.S. defense readiness, raises troop pay by 3.8%, and reinforces the importance of resilient domestic supply chains and robust U.S. manufacturing capacity.
The Senate Special Committee on Aging was back at it this week discussing the woeful predicament of the domestic generic drug industry and its import-facing supply chain. This time, the Committee heard from four generic drug makers opposed to advocacy groups and Washington think tanks.
Witnesses at a Senate hearing on Wednesday, Oct. 29 titled “The Future of Biotech” discussed ways to facilitate reshoring and making it attractive to expand in the U.S. and conduct R&D here instead of in China.
America is finally getting serious about its dangerous dependence on foreign-made generic drugs.
The hearing continued the committee’s efforts to examine and reduce America’s severely dangerous over-dependence on foreign-manufactured generic drugs and address vulnerabilities in the nation’s pharmaceutical supply chain.
The era of global dependency on the CCP is over. For decades, Wall Street, multinational corporations, and globalist institutions helped finance China’s rise at the direct expense of American workers, manufacturers, and national security.
CPA Economist Andrew Rechenberg gave his testimony and answered questions in a four- panelist hearing. It was arguably the most agreeable hearing in years. A bipartisan consensus on America’s generic drug supply chain is nearly fully formed now.
Titled “The New Biotech Cold War: The U.S. Medicine Can’t Afford to Fall Behind China,” the report shows how U.S. biotech – long a pillar of national strength – no longer has a guaranteed edge globally.
